Abstract
Stockpiling and control: A triumph that has emerged from the catastrophe of the severe acute respiratory syndrome coronavirus 2 pandemic has been the rapid development of several potent vaccines. However, 18 months into the pandemic and more than 6 months after vaccine approval, wealthy countries remain the major beneficiaries. Wagner et al . model the consequences of vaccine stockpiling in affluent countries on disease rates in lower- and middle-income countries and the consequences for the eruption of new variants that could jeopardize the early success of vaccines. For countries that can readily access vaccines, it would be better to share vaccines equitably to lower disease burdens in countries with less access, reduce the cost of having to be constantly vigilant for case imports, and minimize virus evolution. —CA
All Related Versions
Funding Information
  • National Science Foundation (CNS-2027908)
  • National Science Foundation (CCF1917819)
  • Centers for Disease Control and Prevention
  • James S. McDonnell Foundation (21st Century Science Initiative Collaborative Award in Understanding Dynamic and Multi-scale Systems)
  • Google
  • Open Philanthropy Project
  • Natural Sciences and Engineering Research Council of Canada (PGS D)
  • C3.ai Digital Transformation Institute and Microsoft Corporation
  • Co-operative Institute for Modelling the Earth System
  • Flu Lab

This publication has 63 references indexed in Scilit: